Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Defence TherapeuticsDTCFF +3.69%21 Net Cash per Share is $-0.01 as of Mar. 2026. GuruFocus rates DTCFF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 769 Biotechnology companies, Defence Therapeutics ranks worse than 130038.88% on this metric.
The historical rank and industry rank for Defence Therapeutics's Net Cash per Share or its related term are showing as below:
During the past 6 years, the highest Price-to-Net-Cash Ratio of Defence Therapeutics was 146.00. The lowest was 47.00. And the median was 79.82.
DTCFF's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.21 * Ranked among companies with meaningful Price-to-Net-Cash only.
Defence Therapeutics (OTCPK:DTCFF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Defence Therapeutics Net Cash per Share Related Terms
Defence Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Defence Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DTCFF vs VRTX, REGN, MRNA: Net Cash per Share Comparison
For the Biotechnology subindustry, Defence Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Defence Therapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Defence Therapeutics's Price-to-Net-Cash falls into.
Defence Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Defence Therapeutics's Net Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Defence Therapeutics (DTCFF) has a Net Cash per Share of $-0.01 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Defence Therapeutics and its competitors. According to the industry distribution chart, Defence Therapeutics ranks #999999 out of 769 companies in the Biotechnology industry.
Is Defence Therapeutics' Net Cash per Share too high?
Defence Therapeutics' current Net Cash per Share is $-0.01. Based on the distribution chart, Defence Therapeutics ranks #999999 out of 769 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Defence Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Defence Therapeutics ranks #999999 out of 769 companies for Net Cash per Share. This places Defence Therapeutics in the lower half of its industry. The industry median Net Cash per Share is 5.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.21, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Defence Therapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Defence Therapeutics's current Net Cash per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current Net Cash per Share of $-0.01. The current Net Cash per Share is $-0.01. Defence Therapeutics' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current Net Cash per Share is $-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
21GF Score
Get the complete analysis for DTCFF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTCFF has been successfully added to your 
